Publikationen

2012

• Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW, Armstrong SA
  Genetic and Pharmacologic Inhibition of b-Catenin Targets Imatinib Resistant Leukemia Stem Cells in CML.
  Cell Stem Cell 2012 Apr 6;10(4):412-24
  Imp.-Fact.:25,943
• Zirm E, Spies-Weisshart B, Heidel F, Schnetzke U, Hochhaus A, Fischer T, Scholl S
  Ponatinib can overcome resistance of FLT3-ITD harbouring additional point mutations including the previously refractory F691I mutation
  Br J Haematol. 2012 May;157(4):483-92
  Imp.-Fact.:4,942
• Müller C, Gardemann A, Keilhoff G, Peter D, Wiswedel I, Schild L
  Prevention of free fatty acid-induced lipid accumulation, oxidative stress, and cell death in primary hepatocyte cultures by a Gynostemma pentaphyllum extract.
  Phytomedicine. 2012 Mar 15;19(5):395-401
  Imp.-Fact.:2,662
• Kasper S, Breitenbuecher F, Heidel F, Hoffarth S, Markova B, Schuler M, Fischer T
  Targeting MCL-1 sensitizes FLT3-ITD positive leukemias to cytotoxic therapies
  Blood Cancer Journal 2012; In print.

2011

• Fischer T
  Rethinking bioactivity of FLT3 inhibitors
  Blood 2011 Mar 24;117(12):3247-8.
  Imp.-Fact.:10,555
• Heidel FH, Mack TS, Razumovskaya E, Blum MC, Lipka DB, Ballaschk A, Kramb J-P, Plutizki S, Rönnstrand L, Dannhardt G, Fischer T
  3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells
  Ann Hematol (2012) 91:331-344
  Imp.-Fact.:2,919
• Koehler K, Dogan E, Koehler M, Heine V, Frommer J
  Surviving the initial phase: Subjective theories of illness of patients suffering from acute leukaemia at the end of first in-patient treatment.
  Z Psychosom Med Psychother. 2011; 2:141-56
  Imp.-Fact.:1,689
• Koehler M, Koehler K, Koenigsmann M, Kreutzmann N, Fischer, T, Frommer J
  Beyond diagnosis: subjective theories of illness in adult patients with acute myeloid leukemia
  Hematology. 2011 Jan;16(1):5-13.
  Imp.-Fact.:1,333
• Heidel FH, Mar BG, Armstrong, SA
  Self-renewal related signaling in myeloid leukemia stem cells
  Int J Hematol. 2011 Aug;94(2):109-17. Epub 2011 Jul 29.
  Imp.-Fact.:1,324

2010

• Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A.
  Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma
  J Clin Oncol. 2010 Dec 1;28(34):5074-80. Epub 2010 Oct 25.
  Imp.-Fact.:17,793
• Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ.
  A Phase IIB Trial of Oral Midostaurin (PKC412), the FLT3 and Multi-targeted Kinase Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and high-risk myelodysplastic syndrome (MDS) with Either Wild-Type or Mutated-FLT3.
  J Clin Oncol. 2010 Oct 1;28(28):4339-45. Epub 2010 Aug 23.
  Imp.-Fact.:17,793
• Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M.
  High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1) - a phase 3, randomised, non-inferiority trial
  Lancet Oncol. 2010 Nov;11(11):1036-47. Epub 2010 Oct 20.
  Imp.-Fact.:14,47
• Kindler T, Lipka DB, Fischer T
  FLT3 as a therapeutic target in AML: still challenging after all these years
  Blood. 2010 Dec 9;116(24):5089-102. Epub 2010 Aug 12.
  Imp.-Fact.:10,555
• Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GL, Jagasia M, Mendrek W, Fischer T, Facon T, Dünzinger U, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J, Kantarjian HM.
  Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
  Leukemia. 2010 Jul;24(7):1299-301. Epub 2010 Jun 3.
  Imp.-Fact.:8,296
• González-Carmona MA, Vogt A, Heinicke T, Quasdorff M, Hoffmann P, Yildiz Y, Schneider C, Serwe M, Bartenschlager R, Sauerbruch T, Caselmann WH.
  Inhibition of hepatitis C virus gene expression by adenoviral vectors encoding antisense RNA in vitro and in vivo.
  J Hepatol. 2010 Nov 30. [Epub ahead of print]
  Imp.-Fact.:7,818
• Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T.
  Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma driven activation of mTOR/p70S6-kinase pathway.
  Oncogene. 2010 Feb 4;29(5):739-51. Epub 2009 Nov 2.
  Imp.-Fact.:7,135
• Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M.
  Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
  Int J Cancer. 2010 Sep 1;127(5):1197-208.
  Imp.-Fact.:4,734
• Schalk E, Bohr URM,König B, Scheinpflug K, Mohren M
  Clostridium difficile-associated diarrhoea, a frequent compliction in patients with acute myeloid leukaemia.
  Ann Hematol 2010;89:9-14
  Imp.-Fact.:2,919
• Krogel C, Fischer T, Heidel F.
  Severe Paraneoplastic Pemphigus in a Patient With Follicular Lymphoma
  Eur J Haematol. 2010 Apr;84(4):365. Epub 2009 Oct 21.
  Imp.-Fact.:2,345
• Bölter, Annette F.; Lange, Julia; Anger, Bernd; Olbricht, Sigrid; Köhler, Michael; Frommer, Jörg
  Wer hat größere Furcht vor einer Verkürzung der Lebensspanne: palliativ oder kurativ behandelte Krebspatienten?
  Psychother Psych Med 2010; 60: 255-261
  Imp.-Fact.:0,904
• Rüsseler, A.V.; Brors, B.; Fischer, Thomas; Hartmann, J.T.; Hartmann, W.; Hohenberger, P.; Lichter, P.; Marx, A.; Mechtersheimer, G.; Penzel, R.; Renner, M.; Schildhaus, H.-U.; Schirmacher, P.; Sievers, E.; Ströbel, P.; Wardelmann, E.; Ziesché, E.; Büttner, R.
  Molekularpathologie von Sarkomen, Erste Ergebnisse des Sarkomforschungsverbundes KoSar
  Pathologe 2010 · [Suppl 2] 31:211-214
  Imp.-Fact.:0,414
• Müller C, Gardemann A, Keilhoff G, Peter D, Wiswedel I, Kropf S, Schild L
  Palmitate protects hepatocytes from oxidative stress and triacylglyceride accumulation by stimulation of nitric oxide synthesis in the presence of high glucose and insulin concentration.
  Free Radic Res. 2010 Dec;44(12):1425-34

2009

• Kayser S, Schlenk RF, Correa Londono M, Breitenbuecher F, Wittke K, Du J, Groner S, Spath D, Krauter J, Ganser A, Dohner H, Fischer T, Dohner K.
  Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.
  Blood. 2009 Sep 17;114(12):2386-92. Epub 2009 Jul 14
  Imp.-Fact.:10,555
• Breitenbuecher F, Schnittger S, Grundler R, Markova B, Carius B, Brecht A, Duyster J, Haferlach T, Huber C, Fischer T.
  Identification of a Novel Type of ITD Mutations Located in Non-Juxtamembrane Domains of the FLT3 Tyrosine Kinase Receptor.
  Blood 2009 Apr 23;113(17):4074-7. Epub 2008 May 15.
  Imp.-Fact.:10,555
• Breitenbuecher F, Markova B, Kasper S, Carius B, Stauder T, Kindler T, Böhmer F, Huber C, Fischer T.
  A Novel Molecular Mechanism of Primary Resistance to FLT3-Kinase Inhibitors in Acute Myeloid Leukaemia.
  Blood 2009 Apr 23;113(17):4063-73. Epub 2009 Jan 14.
  Imp.-Fact.:10,555
• Koehler M, Koenigsmann M, Frommer J.
  Coping with illness and subjective theories of illness in adult patients with haematological malignancies: Systematic review.
  Crit Rev Oncol/Hematol 2009; 69, 237-257
  Imp.-Fact.:4,632
• Dickinson M, Ritchie D, Deangelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM.
  Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
  2009 Oct;147(1):97-101. Epub 2009 Aug 5.
  Imp.-Fact.:4,597
• Heidel F, Lipka D B, Mirea F K, Mahboobi S, Grundler R, Kancha R K, Duyster J, Naumann M, Huber C , Böhmer F D, Fischer T.
  Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
  Br J Haematol. 2009 Mar;144(6):865-874. Epub 2009 Jan 16.
  Imp.-Fact.:4,49
• Schalk E, Neum S, Kranz S, Scheinpflug K, Mohren M .
  Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib.
  Leuk Res 2009;33(3):e6-e7.
  Imp.-Fact.:2,561
• Schalk E, Krogel C, Scheinpflug K, Mohren M.
  Lymphomatoid granulomatosis in a patient with rheumatoid arthritis receiving methotrexate: successful treatment with the anti-CD20 antibody mabthera.
  Onkologie 2009;32:440-441
  Imp.-Fact.:1,545
• Bölter AF, Lange J, Anger B, Olbricht S, Koehler M, Frommer J.
  Who has more anxiety concerning a shortened life span: terminal cancer patients or those in curative therapy?
  Psychother Psych Med: DOI: 10.1055/s-0029-1215597 [Epub ahead of print]
  Imp.-Fact.:1,347
• Kreft A, Springer E, Lipka DB, Kirkpatrick CJ.
  Wild-Type JAK2 Secondary Acute Erythroleukemia Developing after JAK2-V617F-Mutated Primary Myelofibrosis
  Acta Haematologica 2009;122:36-38.
  Imp.-Fact.:1,191
• Schalk E, Scheinpflug K, Mohren M.
  Capillary blood count analyses in clinical practise: a safe, reliable and valid method.
  J Lab Med 2009;33(5):303-309
• Koehler M, Bölter A, Lange J, Dogan E, Heine V, Fischer T, Frommer J.
  Krebspatienten brauchen eine individuelles psychologisches Angebot - 2. Magdeburger Psychoonkologisches Kolloquium.
  Ärzteblatt Sachsen-Anhalt 2009; 20 (4): 50-54.

2008

• Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer C A, Cortes J, Niederwieser D W, Gambacorti C, Stone R M, Goldman J, Fischer T, O'Brien S G, Reiffers J J, Mone M, Krahnke T, Talpaz M, Kantarjian H M .
  Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment.
  Blood 111(3):1039-43, 2008
  Imp.-Fact.:10,432
• Lipka D B, Hoffmann L S, Heidel F, Markova B, Blum M -C, Breitenbuecher F, Kasper S, Kindler T, Levine R L, Huber C, Fischer T .
  LS104, a non ATP-competitive small molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2-V617F positive cells.
  Mol Cancer Ther 7(5): 1176-1184, 2008.
  Imp.-Fact.:5,003
• Kasper S, Breitenbuecher F, Kindler T, Heidel F, Lipka D B, Elliot J, Huber C, Fischer T .
  The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukaemia.
  Leuk Res 32(11):1698-707, 2008.
  Imp.-Fact.:2,39
• Schalk E, Scheinpflug K, Mohren M .
  Correlation of capillary and venous absolute neutrophil counts in adult hematological patients and normal controls.
  Am J Hematol. 2008;83:605
  Imp.-Fact.:1,949
• Scheinpflug K, Schalk E, Mohren M.
  Staphylococcal Scalded Skin Syndrome in an Adult Patient with T-Lymphoblastic Non- Hodgkin's Lymphoma
  Onkologie 2008;31:616-619
  Imp.-Fact.:1,227
• Lipka D, Heidel F, Huber C, Fischer T.
  Entwicklung von Tyrosinkinase-Inhibitoren bei hämatologischen Neoplasien. FLT3 und JAK2 als therapeutische Targets.
  Pharm Unserer Zeit. 2008;37(5):394-403.
• Koehler M, Bölter A, Lange J, Dogan E, Heine V, Frommer J.
  Perspektiven durch Psychoonkologie 2008: Effektivität psychoonkologischer Interventionen.
  Tumorzentrum aktuell 02/2008; 22-27

2007

• Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Löffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A.
  Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia.
  Blood 109:4686-92, 2007
  Imp.-Fact.:10,37
• Graf C, Heidel F, Tenzer S, Radsak M, Solem F, Britten C, Huber C, Fischer T, Wölfel T
  A neoepitope generated by a FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T-cells.
  Blood 109(7):2985-2988, 2007.
  Imp.-Fact.:10,37
• Deininger M, Cortes J, Paquette R, Park B, Niederwieser D, Stone R, Hochhaus A, Reiffers J, Fischer T, Kantarjian H, Baccarani M, Gambacorti-Passerini C, So C, Krahnke T, Gathmann I, Druker D Smith Brian, Guilhot F .
  The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
  Cancer 110:1509-19, 2007.
  Imp.-Fact.:4,582
• Frühauf S, Topaly J, Buss E, Fischer T, Ottmann O, Emmerich B, Müller M, Schuld P, Balleisen L, Hehlmann R, Ho A, Hochaus A .
  Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukaemia in myeloid blast crisis.
  Cancer 109:1543-9, 2007.
  Imp.-Fact.:4,582
• Heidel F, Cortes J, Rücker F G, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T .
  Results of a multicenter phase II trial for older patients with c-kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and Imatinib (IM).
  Cancer 109(5):907-14, 2007.
  Imp.-Fact.:4,582
• Heidel F, Lipka D B, von Auer C, Scharrer I and Hess G.
  Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia
  Thromb Haemost. 2007 Feb;97(2):228-33.
  Imp.-Fact.:3,501
• Kasper S, Kindler T, Breitenbücher F, Sonnenschein S, Böhmer Frank D, Huber C, Fischer T .
  Cross-inhibition of IFN-induced signal transduction by GM-CSF through a block in STAT1- activation.
  J Interferon Cytokine Res 27(11):947-59, 2007.
  Imp.-Fact.:2,472
• Schalk E, Heim MU, Koenigsmann M, Jentsch-Ullrich K.
  Use of capillary blood count parameters in adults.
  Vox Sang 2007;93:348-353
  Imp.-Fact.:2,111
• Al-Batran S E, J T Hartmann, Heidel F, J Stoehlmacher, E Wardelmann, C Dechow, M Düx, J R Izbicki, T Kraus, T Fischer, Jäger E .
  Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.
  Gastric Cancer 10(3):145-52, 2007.
• Drescher D, Moehler M, Gockel I, Frerichs K, Müller A, Biesterfeld S, Holtmann M, Mudter J, Wehler T, Fischer T, Junginger T, Galle P R, Schimanski C C .
  Co-expression of tyrosine kinase receptors in gastric adenocarcinoma - a rationale for a new molecular targeting strategy?
  World J Gastroenterol 13(26):3605-9, 2007.
• Koehler M, Bölter A, Koehler K, Heine V, Koenigsmann M, Frommer J .
  Perspektiven durch Psychoonkologie 2007: Entwicklung und Stand der psychoonkologischen Forschung.
  Tumorzentrum aktuell 02/2007; 18-22.
• Koehler M, von Toll T, Koenigsmann M, Frommer J.
  Die psychosomatische Betrachtung der Hämatologie/Onkologie.
  MedReview 2007; 1, 17-18

2006

• Druker B J, Guilhot F, O'Brien S G, Gathmann I, Kantarjian H, Gattermann N, Deininger M W N, Silver R T, Goldman J M, Stone R M, Cervantes F, Hochhaus A, Powell B L, Gabrilove J L, Rousselot P, Reiffers J, Cornelissen J J, Hughes T, Agis H, Fischer T Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators.
  Five-Year Follow-up of Imatinib Therapy for Newly Diagnosed Chronic Myeloid Leukemia in Chronic-Phase Shows Sustained Responses and High Overall Survival.
  New England Journal of Medicine 355:2408-17, 2006
  Imp.-Fact.:51,296
• Heidel F, Solem F K, Breitenbuecher F, Lipka D B, Kasper S, Thiede H M, Serve C Brandts H, Roesel J, Giles F, Feldman E, Ehninger G, Schille G J, Nimer S, Stone R M, Kindler T, Cohen P S, Huber C, Fischer T .
  Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia (AML) by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
  Blood 107(1):293-300, 2006.
  Imp.-Fact.:10,37
• Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K .
  A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
  Clinical Cancer Research 1;12(15):4628-35, 2006.
  Imp.-Fact.:6,177
• Mahboobi S, Uecker A, Sellmer A, Cénac C, Höcher H, Pongratz H, Eichhorn E, Hufsky H, Trümpler A, Sicker M, F Heidel, Fischer T, Stocking C, Elz S, Böhmer F D, Dove S .
  Novel Bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinases.
  Journal of Medicinal Chemistry 49: 3101-3115, 2006.
  Imp.-Fact.:5,115
• Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J, Maziarz R, Olavarria E, Verdonck L, Schaefer K, Boqué C, Faber E, Nagler A, Pogliani E, Russell N, Volin L, Schanz U, Doelken G, Kiehl M, Fauser A, Druker B, Sureda A, Iacobelli S, Brand R, Krahl R, Lange T, Hochhaus A, Gratwohl A, Kolb H, Niederwieser D, European Blood and Marrow Transplantation Group.
  The effect of prior exposure to imatinib on transplant-related mortality.
  Haematologica. 2006 Apr;91(4):452-9
  Imp.-Fact.:5,032
• Schalk E, Mohren M, Jentsch-Ullrich K, Dombrowski F, Franke A, Koenigsmann M.
  Zygomycoses in patients with acute leukaemia
  Ann Hematol 2006;85:327-32.
  Imp.-Fact.:2,254
• Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg J, Siebler J, Weinmann A, Teufel A, Wörns M, Fischer T, Strand S, Lohse A W, Galle P R .
  Histone deacetylase inhibition by valproic acid downregulates c-FLIP and sensitizes hepatoma cells towards CD95- and TRAIL-receptor mediated apoptosis and chemotherapy.
  Oncology Reports 15: 227-230, 2006.
  Imp.-Fact.:1,567
• Scheinpflug K, Schalk E, Reschke K, Franke A, Mohren M .
  Diabetes insipidus due to herpes encephalitis in a patient with diffuse large cell lymphoma. A case report.
  Exp Clin Endocrinol Diabetes. 2006 Jan;114(1):31-4.
  Imp.-Fact.:1,356
• Koehler M, Franke A, Koenigsmann M .
  Psycho-Onkologie in der Klinik für Hämatologie und Onkologie der Otto-von-Guericke-Universität Magdeburg.
  Ärzteblatt Sachsen-Anhalt 2006; 17 (7), 16-35.
• Koehler K, Kreutzmann N, Koenigsmann M, Koehler M, Franke A, Frommer J .
  Normalisierung durch Übernahme der Patientenrolle: Subjektive Krankheitsvorstellungen, Bewältigungsstrategien und Zukunftserwartungen bei Patienten mit akuter Leukämie nach Adaptation an den Klinikalltag.
  Psychotherapie und Sozialwissenschaft 2006; 1, 11-27.
• Koenigsmann M, Koehler M, Franke A, Frommer J.
  Acute leukaemia in adults: researching the patient’s perspective.
  Leukemia 2006; 20, 206-207.

2005

• Heß G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Waßmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann A J, Kindler T, Haus U, Geschaidmeier H, Huber C, Fischer T .
  Sustained complete molecular remissions after treatment with Imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia (CML): Results of a prospective phase II open-label multicenter study.
  Journal of Clinical Oncology 23(30):7583-93, 2005
  Imp.-Fact.:11,81
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Berdel W, H -E Reis, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, ldaoud A A, Pawaresch R,.
  Front-line therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisione (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of
  Blood, 106:3725-32, 2005.
  Imp.-Fact.:10,131
• Choudhary C, Schwable J, Brandts C, Tickenbrock L, Sargin B, Kindler T, T Fischer, Berdel W E, Muller-Tidow C, Serve H .
  AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
  Blood. 106(1):265-73, 2005.
  Imp.-Fact.:10,131
• Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer S D, Gratwohl A, Choudhary C, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen P S, Huber C, Fischer T .
  Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
  Blood 105(1):335-40, 2005
  Imp.-Fact.:10,131
• Schalk E, Mohren M, Koenigsmann M, Buhtz P, Franke A, Jentsch-Ullrich K.
  Metastatic adrenal neuroblastoma in an adult.
  Onkologie 28(2005), Nr. 6-7, S. 353 - 355
  Imp.-Fact.:1,283
• Kreft A, Büsche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick C J .
  The Incidence of Myelofibrosis in Essential Thrombocythaemia, Polycythaemia vera and Chronic Idiopathic Myelofibrosis: A Retrospective Evaluation of Sequential Bone Marrow Biopsies.
  Acta Haematologica 113(2):137-43, 2005.
  Imp.-Fact.:1,229
• Schalk E, Franke A, Koenigsmann M.
  Akute myeloische Leukämie mit pulmonaler Manifestation.
  Pneumologie 59(2005), Nr. 9, S. 588 - 591

2004

• Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B, Duyster J, Peschel C, Kirkpatrick C J, Theobald M, Gschaidmeier H, Huber C, Fischer T .
  The efficacy and safety of imatinib in adult patients with c-kit positive acute myeloid leukemia.
  Blood, 15;103(10):3644-54, 2004
  Imp.-Fact.:9,782
• Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A, Solano C, Simonsson B, Sonnen R, Diehl V, Fischer T, Caballero D, Littlewood T, Noppeney R, Hossfeld D, Jost L, Delabarre F, Marcus R .
  Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double blind, randomized trial.
  Bone Marrow Transplantation 34(11):955-62, 2004.
  Imp.-Fact.:2,101
• Kreft A, Burg J, Fischer T, Kirkpatrick C J.
  Essential Thrombocythaemia Terminating in Pure Erythroleukaemia
  Am J Hematol 77(2):140-3, 2004.
  Imp.-Fact.:1,701
• Koenigsmann M, Knauf W, Herold M, Pasold R, Müller G, Eschenburg H, Kahl C, Lakner V, Assmann M, Jentsch-Ullrich K, Mohren M, Bartsch R, Franke A.
  Fludarabine and bendamustine in refractory and relapsed indolent lymphoma : a multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO).
  Leuk. Lymphoma 45(2004), Nr. 9, S. 1821 - 1827
  Imp.-Fact.:1,163

2003

• O’Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, Cornelissen J, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen J L, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman J, Talpaz M, Taylor K, Verhoe.
  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
  New England Journal of Medicine 348(11):994-1004; 2003.
  Imp.-Fact.:34,833
• Kindler T, Breitenbuecher F, Marx A, Gschaidmeier H, Gamm H, Huber C, Fischer T .
  Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
  Blood 101 (8): 2960-2962, 2003.
  Imp.-Fact.:10,12
• Johnson B E, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski M O, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, T Le Chevalier .
  Phase II Study of Imatinib Mesylate (Glivec®) for Patients with Small Cell Lung Cancer.
  Clinical Cancer Research, 9:5880-5887, 2003.
  Imp.-Fact.:6,511
• Nowicki M O, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T .
  Chronic myelogenous leukemia molecular signature
  Oncogene, 22:3952-3963, 2003.
  Imp.-Fact.:6,495
• Müller MC, Gattermann N, Lahaye T, Deininger M W N, Berndt A, Frühauf S, Reckzeh B, Fischer T, Hossfeld D K, Schneller F, Krause S, Nerl C, Sayer H G, Ottmann O G, Waller C, Aulitzky W, Coutre P Le, Freund M, Merx K, Paschka P, König H, Kreil S, Berger U,.
  Dynamics of BCR-ABL mRNA expression in first line therapy of chronic myelogenous leukemia patients with imatinib or interferon-alpha/ara-C.
  Leukemia, 17(12):2392-400, 2003.
  Imp.-Fact.:5,116
• Olavarria E, Ottmann O G, Deininger M, Clark R E, Bandini G, Byrne J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann B, Niederwieser D, Fischer T .
  Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
  Leukemia, 17(9):1707-12, 2003
  Imp.-Fact.:5,116
• Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, Gschaidmeier H, Huber C, Fischer T .
  In bcr-abl - positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by STI571 and Ara-C.
  Leukemia, 17:999-1009, 2003.
  Imp.-Fact.:5,116
• O'Brien S G, Meinhardt P, Peng B, Beck J, Dutreix C, Mehring G, Milosavljev S, Huber C, Capdeville R, Fischer T .
  Effects of Glivec® on pharmacokinetics of simvastatin, a cytochrome 3A4 substrate in patients with Chronic Myeloid Leukemia.
  British Journal of Cancer 89(10):1855-9, 2003.
  Imp.-Fact.:3,894
• Hess G, Flohr T, Huber C, Derigs H G, Fischer T .
  Safety and feasibility of CHOP/Rituximab induction treatment followed by high dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated indolent B-NHL.
  Bone Marrow Transplantation 31:775-782, 2003
  Imp.-Fact.:2,172
• Ullmann A J, Hess G, Kolbe K, Friedrich-Freksa A, Meyer R G, Gschaidmeier H, Huber C, Fischer T .
  Current Results on the Use of Imatinib Mesylate in Patients with Relapsed Philadelphia Chromosome Positive Leukemia after Allogeneic or Syngeneic Haematopoietic Stem Cell Transplantation.
  The Keio Journal of Medicine, 52(3):182-8, 2003.

2002

• Kantarjian H, Sawyers C L, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederweiser D, Stone R, Goldman J, T Fischer, P Cony-Makhoul, Miller C, M Tallman, O’Brien S, Brown R, Schuster M, Gratwohl A, Loughran T, Mandelli F, Saglio G, Ottmann.
  Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
  New England Journal of Medicine 346 (9): 645 - 652, 2002.
  Imp.-Fact.:31,736
• Talpaz M, Silver R T, Druker B, Goldman J M, Gambacorti-Passerini C, Guilhot F, Schiffer C A, Fischer T, Niederweiser D, O’Brien S G, Hochhaus A, Ottmann O G, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon F X, Fernandes-Reese S, Gathmann I, Capdeville R.
  Glivec® (imatinib mesylate) Induces Durable Hematologic, Cytogenetic Responses in Patients with Accelerated Phase Chronic Myeloid Leukemia: Results of a Phase II Study.
  Blood 99: 1928 -1937, 2002.
  Imp.-Fact.:9,631
• Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C, Ottmann O G, Schiffer C A, Talpaz M, Guilhot F, Deininger M W N, Fischer T, O’Brien S G, Stone R, Gambacorti-Passerini C, Russell N, Reiffers J, Shea T, Chapuis B, Coutre S, Tura S, Morra E, Larso.
  Glivec® (imatinib mesylate) Induces Hematologic, Cytogenetic Responses in Patients with Chronic Myeloid Leukemia in Myeloid Blast Crisis: Results of a Phase II Study.
  Blood 99: 3530-9, 2002.
  Imp.-Fact.:9,631
• Ottmann O G, Druker B J, Sawyers C L, Goldman J M, Mahon F X, Silver R T, Tura S, Fischer T, Deininger M, Schiffer C A, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O’Brien S G .
  Glivec® (imatinib mesylate) Induces Hematologic, Cytogenetic Responses in Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Leukemias: Results of a Phase II Study.
  Blood 100: 1965-1971, 2002.
  Imp.-Fact.:9,631
• Fischer T, Reifenrath C, Hess G, Corsetti M T, Kreil S, Beck J, Meinhardt P, Beltrami G, Schuch B, Gschaidmeier H, Hehlmann R, Hochhaus A, Carella A, Huber C.
  Safety and efficacy of STI-571 (GlivecTM) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation.
  Leukemia 16:1220-1228, 2002.
  Imp.-Fact.:4,693